OCV

Ozette is a life sciences data startup company that develops an artificial intelligence-enabled immune monitoring platform. It empowers scientists to quickly extract reliable insights from single-cell data across instruments, experiments, and disease states, with a focus on cancer patients. The data can be used by doctors to diagnose and prescribe medication with greater accuracy. In 2020, co-founders Raphael Gottardo, Greg Finak, Ali Ansary, and Evan Greene headquartered the life science company in Seattle, Washington.

Ockam Inc. provides a server less platform for secure Internet-of-things (IOT) development. The company’s tool enables to interconnect hardware with software services and facilitate the exchange of information within connected systems; manage identities, cryptographic keys, and credentials for devices and services; and optimize connectivity and messaging for the exchange of information between entities and applications. Additionally, it connects application developers and system integrators; hardware and chipset engineers; and cloud service product managers. Ockam Inc. was founded in 2017 and is headquartered in San Francisco, California.

Rad AI empowers radiologists for the future.

ByHeart, Inc. is an infant and baby nutrition company focused on developing products that support various aspects of children's health, including immune, microbiome, cognitive, and digestive health. Established in 2016 and headquartered in New York, the company operates with facilities in Pennsylvania. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative foods and formulas, prioritizing natural ingredients and small-batch production to ensure quality. The company's commitment to promoting healthy growth and providing peace of mind for parents distinguishes it in the infant nutrition market.

Orca AI advances the maritime industry by providing intelligent navigation solutions, preventing collisions and saving lives. We ensure safety in waterways and deep waters by staying committed in our vision to reduce human-caused errors through intelligent automated vessels.

Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Praxis Precision Medicines offers drug development services. The company was formerly known as EpiPM Therapeutics. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

ByHeart, Inc. is an infant and baby nutrition company focused on developing products that support various aspects of children's health, including immune, microbiome, cognitive, and digestive health. Established in 2016 and headquartered in New York, the company operates with facilities in Pennsylvania. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative foods and formulas, prioritizing natural ingredients and small-batch production to ensure quality. The company's commitment to promoting healthy growth and providing peace of mind for parents distinguishes it in the infant nutrition market.

SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation, providing organizations with tools to enhance their security posture. Founded in 2014 and based in Sunnyvale, California, with an additional location in Tel Aviv, Israel, SafeBreach offers a comprehensive platform that simulates hacker techniques to identify vulnerabilities within a network. Its platform utilizes an extensive Hacker's Playbook, which includes real-world breach methods, to proactively predict potential attacks and validate existing security controls. By integrating with various security information and event management systems and other cybersecurity tools, SafeBreach enables continuous visibility into security issues, allowing businesses to detect and remediate potential breaches before they can be exploited by actual attackers. The company is supported by notable investors, including Sequoia Capital and Deutsche Telekom Capital.

Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Figure8​ is an experience-first development company to realize, recognize, and reignite relationships with the people and places around them. The company is built on core tenets of imagination, connection, and creativity. Figure8 was founded by Manish Vora and Maryellis Bunn in 2016 and is headquartered in New York, USA.

Ossio Inc., founded in 2014 and headquartered in Woburn, Massachusetts, develops and manufactures innovative orthopedic medical devices. The company specializes in OSSIOfiber, a bio-integrative implant designed for bone regeneration. Ossio aims to revolutionize the orthopedic fixation market, which includes screws, pins, and plates, by providing a non-permanent alternative to traditional metal implants. Their Intelligent Bone Regeneration Technology seeks to enhance patient healing and restore stability and mobility without leaving permanent materials behind. OSSIOfiber is engineered to offer the mechanical strength needed for secure fixation while promoting natural bone growth, thereby addressing the shortcomings of existing bio-resorbable materials that often lead to inflammation and weakness. Through its advancements, Ossio is positioned to transform orthopedic care for patients, healthcare providers, and payors alike.

Invoice2go is a technology company focused on simplifying the business processes of small business owners and freelancers worldwide. The platform provides essential tools for creating estimates and invoices, managing appointments, and tracking jobs, all designed to enhance organization and professionalism. Users can also accept various payment methods directly through the application, facilitating cash flow management and business growth. Founded by a small business owner with ties to trades, Invoice2go aims to empower its users by streamlining their operations. The platform is utilized by over 210,000 small business owners across more than 160 countries, enabling them to send approximately $24 billion in invoices annually. With a team based in Redwood City, California, and Sydney, Australia, Invoice2go combines expertise from various industries to continuously improve its offerings.

Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.